GE

314.05

+0.39%↑

RTX

177.49

-1.35%↓

GEV.US

577.41

+0.32%↑

HON

214.26

-0.42%↓

UNP

218.02

-0.56%↓

GE

314.05

+0.39%↑

RTX

177.49

-1.35%↓

GEV.US

577.41

+0.32%↑

HON

214.26

-0.42%↓

UNP

218.02

-0.56%↓

GE

314.05

+0.39%↑

RTX

177.49

-1.35%↓

GEV.US

577.41

+0.32%↑

HON

214.26

-0.42%↓

UNP

218.02

-0.56%↓

GE

314.05

+0.39%↑

RTX

177.49

-1.35%↓

GEV.US

577.41

+0.32%↑

HON

214.26

-0.42%↓

UNP

218.02

-0.56%↓

GE

314.05

+0.39%↑

RTX

177.49

-1.35%↓

GEV.US

577.41

+0.32%↑

HON

214.26

-0.42%↓

UNP

218.02

-0.56%↓

Search

Ocugen Inc

Open

1.51 -3.21

Overview

Share price change

24h

Current

Min

1.49

Max

1.56

Key metrics

By Trading Economics

Income

611K

-15M

Sales

-108K

1.4M

Profit margin

-1,073.489

Employees

95

EBITDA

724K

-13M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+459.21% upside

Dividends

By Dow Jones

Next Earnings

5 Nov 2025

Market Stats

By TradingEconomics

Market Cap

188M

506M

Previous open

4.72

Previous close

1.51

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Ocugen Inc Chart

Past performance is not a reliable indicator of future results.

Related News

28 Oct 2025, 23:50 UTC

Hot Stocks

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28 Oct 2025, 23:25 UTC

Earnings

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28 Oct 2025, 23:18 UTC

Earnings

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28 Oct 2025, 22:20 UTC

Earnings

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28 Oct 2025, 22:13 UTC

Earnings

Wal-Mart de Mexico Net Profit Falls in 3Q

28 Oct 2025, 21:38 UTC

Earnings

Correction to Visa Sales Jump Article

28 Oct 2025, 21:17 UTC

Earnings

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28 Oct 2025, 21:07 UTC

Earnings

Visa Sales Jump as Consumers Keep Spending -- Update

28 Oct 2025, 21:02 UTC

Earnings

Mondelez Tempers Outlook as Costs Rise

28 Oct 2025, 23:51 UTC

Market Talk

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28 Oct 2025, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28 Oct 2025, 23:02 UTC

Earnings

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28 Oct 2025, 23:01 UTC

Earnings

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28 Oct 2025, 22:46 UTC

Earnings

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28 Oct 2025, 22:45 UTC

Earnings

SK Hynix 3Q Net KRW12.6T >000660.SE

28 Oct 2025, 22:44 UTC

Earnings

SK Hynix 3Q Rev KRW24.44T >000660.SE

28 Oct 2025, 22:43 UTC

Earnings

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28 Oct 2025, 22:42 UTC

Earnings

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28 Oct 2025, 22:40 UTC

Earnings

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28 Oct 2025, 22:40 UTC

Earnings

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28 Oct 2025, 22:22 UTC

Earnings

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28 Oct 2025, 22:22 UTC

Earnings

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28 Oct 2025, 22:22 UTC

Earnings

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28 Oct 2025, 22:20 UTC

Earnings

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28 Oct 2025, 22:02 UTC

Earnings

Review & Preview: Earnings Extravaganza -- Barrons.com

28 Oct 2025, 21:42 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

28 Oct 2025, 21:42 UTC

Market Talk
Earnings

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28 Oct 2025, 21:20 UTC

Earnings

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28 Oct 2025, 21:19 UTC

Earnings

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28 Oct 2025, 21:18 UTC

Earnings

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Peer Comparison

Price change

Ocugen Inc Forecast

Price Target

By TipRanks

459.21% upside

12 Months Forecast

Average 8.5 USD  459.21%

High 15 USD

Low 4 USD

Based on 4 Wall Street analysts offering 12 month price targets forOcugen Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

0.6818 / 0.74Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

No Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
help-icon Live chat